Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19

202331 citationsJournal Articlegreen Open Access

Authors

National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

Good health and well-being

Published in: Annals of Internal Medicine

Volume 176, Issue 5, pp. 658-666

Field-Weighted Citation Impact: 6.02